Special Issue "Polypharmacology and Multitarget Drug Discovery"
Deadline for manuscript submissions: closed (20 May 2017)
Prof. Dr. Cornelis J. Van der Schyf
Vice President for Research and Dean of the Graduate School, Professor of Biomedical and Pharmaceutical Sciences, Idaho State University, 921 S. 8th Avenue, Pocatello, ID 83209-0001, USA
Interests: multitarget anti-alzheimer and anti-parkinson agents; hybrid compounds; multifunctional NMDA antagonists; MAO inhibitors; natural products
Over the past two decades, a resurging interest in the development of multi-target directed compounds to treat diseases with complex pathological mechanisms has grown into one of the most actively investigated fields in the search for new drug molecules. Such drug molecules—previously referred to as “dirty drugs”, due to their clinically challenging and complex side-effect profiles in general use—simultaneously target multiple etiologies that have been found to be important modulators in a variety of diseases. This approach has been found to have significant promise for translation into the clinic and may be more effective than using one compound specifically targeted towards one molecular pathology or even a polypharmaceutical approach using a cocktail of two or more “pure” target-directed drugs.
However, the rational design and development of multi-target directed molecules remain one of the most challenging tasks facing medicinal chemists today. These challenges center around these key questions: (1) how does one achieve optimized activity towards multiple molecular targets of interest in the disease pathological pathways; (2) while simultaneously preserving drug-like properties and a balanced pharmacodynamics profile in one molecule; and (3) without compromising favorable pharmacokinetics?
Several chemical classes of structures have been found to be useful as scaffolds to be considered for multitarget drugs in drug development programs.
This Special Issue attempts to provide a synopsis of current research by leaders in the field, and will exemplify the use of an array of approaches and particular compounds of interest used as starting molecules to develop multifunctional drugs, and will emphasize innovative applications of multifunctional and hybrid molecules in challenging and complex diseases.
We welcome original articles and short communications as well as a limited number of review articles on novel methods and approaches for multi-target directed drug development. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Prof. Dr. Cornelis J. Van Der Schyf
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access bimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- multitarget-directed molecules
- constructive polypharmacology
- hybrid molecules
- drug discovery
- rational design
- imaging agents
- complex diseases